Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

NCT05636852 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT05636852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05636852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging
Lead sponsor
GE Healthcare
Phase
Phase 2
Overall status
Terminated
Start date
April 24, 2023
Completion date
June 8, 2024
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

movement disorders, parkinson disease